V-10 is peptide that develops mature blood vessels for treatment of vascular disease, effecting 8 million Americans.
NO FDA approved revascularization therapies exists.
Shown animal efficacy (as required by the FDA), and preliminary safety studies in mice and rats.
Premium pricing allows $30B per annum.
Key-opinion leaders mention excitement and the potential for this angiogenic therapy.
Raise: complete pre-clinical studies for FDA IND filing.